Observational studyScientific reports2026
Central and peripheral glutamatergic biomarkers delineate heterogeneous clinical phenotypes in olanzapine-treated schizophrenia.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study aimed to identify central and peripheral glutamatergic biomarkers underlying heterogeneous clinical phenotypes in olanzapine-treated patients with schizophrenia, with the goal of informing biomarker-guided personalized therapy. We conducted a cross-sectional observational study of 51 adults with schizophrenia receiving chronic olanzapine treatment (mean duration = 5.6 years), integrating clinical assessments with peripheral neurochemical profiling and magnetic resonance spectroscopy (MRS) of the anterior and posterior cingulate cortices. Partial correlations controlling for age, sex, and treatment duration revealed significant associations: higher serum serotonin correlated with more severe negative symptoms (ρ = 0.32, p = 0.029), and increased cingulate Glx ratios were linked to greater depressive burden (ρ = 0.31, p = 0.031). Elevated serum glutamic acid was associated with overall psychopathology, whereas lower serum and cingulate glutamine levels were related to more severe symptoms and higher olanzapine exposure. Hierarchical clustering on principal components (HCPC) identified three phenotypic subgroups: (1) low-symptom, dose-efficient responders; (2) high-symptom, dose-resistant patients with cingulate hypoglutamatergia; and (3) younger individuals with elevated Glx ratios and moderate exposure, suggestive of a hyperglutamatergic, neurodevelopmental profile. These findings demonstrate that central and peripheral glutamatergic markers delineate distinct clinical phenotypes of olanzapine response in schizophrenia, shaped by both neurochemical and demographic factors. Stratification based on glutamatergic profiles and symptom patterns may contribute to the development of precision psychiatry approaches. To our knowledge, this is the first study to integrate central and peripheral glutamatergic biomarkers with multivariate phenotyping in a naturalistic olanzapine-treated cohort, identifying (i) a low-symptom, low-exposure phenotype, (ii) a high-symptom, high-exposure phenotype characterised by reduced cingulate Glx, and (iii) a younger phenotype with elevated cingulate Glx ratios, consistent with, though not confirmatory of, a neurodevelopmental trajectory. These findings are exploratory and warrant prospective validation to determine their potential utility for biomarker-guided treatment stratification in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.